Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs
Mutsaers, A.J.; Glickman, N.W.; Denicola, D.B.; Widmer, W.R.; Bonney, P.L.; Hahn, K.A.; Knapp, D.W.
Journal of the American Veterinary Medical Association 220(12): 1813-1817
2002
ISSN/ISBN: 0003-1488
PMID: 12092954
DOI: 10.2460/javma.2002.220.1813
Accession: 010620506
Objective: To evaluate the antitumor and toxic effects of treatment with doxorubicin combined with piroxicam or doxorubicin alone for multicentric lymphoma in dogs. Design: Nonrandomized clinical trial. Animals: 75 dogs with multicentric lymphoma. Procedure: 33 dogs were treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) and piroxicam (0.3 mg/kg (0.14 mg/lb), PO, q 24 h); results were compared with a historical control group of 42 dogs treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) alone. Results: The percentages of dogs that had remission with doxorubicin-piroxicam treatment (79%) or doxorubicin treatment alone (74%) were not significantly different. Median duration of first remission was 130 days with doxorubicin-piroxicam and 147 days with doxorubicin alone; these values were not significantly different. Severe toxicosis was observed in 22% of dogs treated with doxorubicin-piroxicam and 17% of dogs treated with doxorubicin alone. Conclusions and Clinical Relevance: Both treatment protocols were efficacious and well tolerated. The doxorubicin-piroxicam treatment was no more effective regarding response rate, remission duration, or survival duration, compared with the control group treated with doxorubicin alone.